Piperazinedione (NSC 135758) and total body irradiation as an ablative bone marrow transplantation regimen in mice.
Piperazinedione, an antitumor antibiotic with activity against leukemia, has been incorporated into a regimen for clinical bone marrow transplantations. Studies were conducted to evaluate the effect of piperazinedione on hemopoietic stem cells and the recovery of hemopoiesis after syngeneic transplantation. The effect of piperazinedione on hemopoietic stem cells is short in duration (nadir day 1). Myelosuppression does not appear to be its limiting toxicity, since mice could not be rescued by syngeneic bone marrow at increased doses of piperazinedione. Piperazinedione given prior to total body irradiation has an enhancing effect on colony-forming unit culture (CFUC) and colony-forming unit spleen (CFUS) recovery from day 7 to day 90 post transplantation when compared with total body irradiation alone.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D051379:Mice; D008815:Mice, Inbred Strains; D010879:Piperazines; D014916:Whole-Body Irradiation
D000903:Antibiotics, Antineoplastic; D010879:Piperazines; C003905:3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione